New medical devices working with particles so small that they are invisible to the human eye are paving the way for earlier cancer detection, helping save lives.
Cancer is one of the most dreaded words in the English language. It kills around two million people in Europe every year – approximately four times the population of Luxembourg.
Early detection could help prevent a third of cases, but, with current technology, tumours can grow for 10 years or longer before blood tests will detect them.
Tommaso Foglia of Innova, an innovation support consulting firm that is involved in the EU-funded Namdiatream project, said: ‘Although some types of cancer can be treated more effectively than others, and each treatment – such as chemotherapy or radiotherapy - has specific advantages and drawbacks, it is well known that one of the most effective ways to improve cancer’s treatment is its early diagnosis.’
This is the motivation behind Namdiatream, a four-year project that brought together a team of 22 scientists and company executives.
‘One of the most effective ways to improve cancer’s treatment is its early diagnosis.’
Tommaso Foglia, Innova
‘Our strategic vision is to reduce cancer mortality and social costs for national healthcare systems (and) to increase the quality and expectancy of life of citizens worldwide,’ Foglia said.
The project, which runs until 2014, takes its name from the very products it has created - nanotechnological toolkits for multi-modal disease diagnostics and treatment monitoring.
Visually, one would find it hard to measure their work: one million nanometres make up the head of a pin, whilst a human hair is around 60 000 nanometres in diameter.
‘Namdiatream addresses the widespread social need developing ultra-sensitive devices for the early diagnosis and imaging of three widespread cancer types: lung, breast and prostate cancer,’ Foglia said.
Nanotechnology has already provided many different medical solutions for diagnostics. Nanoparticles have outstanding magnetic, optical and electronic features that, once introduced in drug delivery systems, can enable rare approaches for cancer treatment and other diseases.
Namdiatream’s solution is to develop microscopic tools able to detect and quantify specific tumour markers that can be found in the human body when cancer cells are present.
The Namdiatream project is coordinated by Prof. Yuri Volkov (Trinity College Dublin, Ireland)
Their work builds on existing efforts, such as wafer thin ‘lab-on-a-chip’ diagnostic tests, and will provide doctors with tests so sensitive they can be used on tiny amounts of blood or saliva.
‘The diagnosis can be performed using micro-litre volumes of biological fluids thus minimising the invasiveness and costs of diagnostic procedures,’ Foglia explained.
‘This fosters the early detection of cancer by means of routine screening among the population, encourages a prompt intervention to treat the disease (and) permits a more effective evaluation of disease progression during the treatment,’ he added.
Industry has already shown interest in the project. Two companies are actively collaborating with many academic and research partners, said Foglia. And they have shown a clear commitment to translate breakthroughs into innovative industrial applications’.
When an outbreak strikes, speed is critical. Health workers must act quickly not only to contain and treat an emerging or re-emerging disease, but also to use this window to evaluate potential treatments and vaccines. And the challenge becomes even greater in sub-Saharan Africa when you’re trying to develop new approaches in the face of multiple emerging diseases.
Understanding the progression from the stepping reflex to independent walking could help find new therapies for children with cerebral palsy (CP) – a movement disability caused by brain damage before, during or shortly after birth.
Nature provides people with everything from food and water to timber, textiles, medicinal resources and pollination of crops. Now, a new approach aims to measure exactly what a specific ecosystem supplies in order to incentivise decision-makers and businesses to help combat biodiversity loss.
Europe’s position on privacy, regulation and competition could be a key way to attract entrepreneurs who share those values but there is still some work to do in encouraging ambition, according to Nicklas Bergman, a Swedish entrepreneur and technology investor. Over the past two years, he and other entrepreneurs have advised the European Commission on the design of the European Innovation Council (EIC), an initiative to support companies, researchers and entrepreneurs hoping to start their own business or scale up their projects internationally. The second phase of the pilot was launched on 18 March 2019.
To protect species, we need to speak the language of business, say experts.
He has advised the EU on its new European Innovation Council.
Species loss needs urgent international action, says Prof. Georgina Mace.